- Home
- TUSK vs CNTB Comparison
TUSK vs CNTB Comparison
Compare TUSK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TUSK | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 140.4M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TUSK | CNTB |
|---|---|---|
| Price | $3.16 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 102.0K | ★ 1.6M |
| Earning Date | 05-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $44,292,000.00 | $64,000.00 |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.72 | $1.06 |
| 52 Week High | $3.92 | $3.82 |
Technical Indicators
Market Signals| Indicator | TUSK | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 32.54 |
| Support Level | $2.98 | N/A |
| Resistance Level | $3.32 | $2.78 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 65.67 | 11.45 |
Price Performance
Historical ComparisonAbout TUSK Mammoth Energy Services Inc.
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.